Yıl: 2016 Cilt: 26 Sayı: 3 Sayfa Aralığı: 229 - 237 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Safety of psychotropic medications in pregnancy: an observational cohort study

Öz:
Objective: The question of harmfulness of the psychiatric drugs creates a major dilemma for pregnant women. The risks associated with prenatal psychotropic drug exposure are often overestimated. It is unclear that psychotropic medication or disorders themselves increase the risk of adverse pregnancy outcomes. The purpose of this study is to generate data about the safety of psychotropic drugs in pregnancy and maternal characteristics of the pregnant women exposed to these drugs. Method: An observational cohort study was performed. Pregnancy outcomes of 135 pregnancies after psychotropic drug exposure are compared to a control group of 275 pregnancies. Results: There were no statistically significant differences in rates of major malformations, miscarriages, and preterm deliveries between the two groups. However, the rate of elective abortions was higher in the exposed group compared to the control group (11.1% vs. 5.1%, respectively; RR 2.18; 95% CI: 1.09-4.39), and most of them were nulliparous (45.2%). The majority of the pregnant women did not smoke cigarettes and no alcohol consumption was reported in both groups. Conclusion: Our study showed that there was a tendency to terminate pregnancy among women exposed to psychotropic drugs. An accurate risk assessment about drug safety and informing pregnant women would help to prevent unnecessary terminations of pregnancies
Anahtar Kelime:

Konular: Farmakoloji ve Eczacılık
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • . Frieder A, Dunlop AL, Culpepper L, Bernstein PS. The clinical content of preconception care: women with psychiatric conditions. Am J Obstet Gynecol 2008;199(6 Suppl. 2):S328-S32. [CrossRef]2. DiPietro JA. The role of prenatal maternal stress in child development. Curr Dir Psychol Sci 2004;13(2):71-4. [CrossRef]3. Oyebode F, Rastogi A, Berrisford G, Coccia F. Psychotropics in pregnancy: safety and other considerations. Pharmacol Ther 2012;135(1):71-7. [CrossRef]4. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, et al. Relapse of depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006;295(5):499-507. [CrossRef]5. Greene MF. Teratogenicity of SSRIs - serious concern or much ado about little? N Engl J Med 2007;356(26):2732-3. [CrossRef]6. Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr Scand 2013;127(2):94-114. [CrossRef]7. Malm H, Sourander A, Gissler M, Gyllenberg D, Hinkka-Yli-Salomäki S, McKeague IW, et al. Pregnancy complications following prenatal exposure to SSRIs or maternal msychiatric disorders: results from population-based national register data. Am J Psychiatry 2015;172(12):1224-32. [CrossRef]8. Huybrechts KF, Palmsten K, Avorn J, Cohen LS, Holmes LB, Franklin JM,et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 2014;370(25):2397-407. [CrossRef]9. Hironaka M, Kotani T, Sumigama S, Tsuda H, Mano Y, Hayakawa H, et al. Maternal mental disorders and pregnancy outcomes: a clinical study in a Japanese population. J Obstet Gynaecol Res 2011;37(10):1283-9. [CrossRef]10. Jones I, Chandra PS, Dazzan P, Howard LM. Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period. Lancet 2014;384(9956):1789-99. [CrossRef]11. Sadowski A, Todorow M, Yazdani Brojeni P, Koren G, Nulman I. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. BMJ Open 2013;3(7):e003062. [CrossRef] 12. Terrana N, Koren G, Pivovarov J, Etwel F, Nulman I. Pregnancy outcomes following in utero exposure to second-generation antipsychotics: systematic review and meta-analysis. J Clin Psychopharmacol 2015;35(5):559-65. [CrossRef]13. Jentink J, Loane MA, Dolk H, Barisic I, Garne E, Morris JK,et L. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010;362(23):2185- 93. [CrossRef]14. Garbis H, McElhatton PR. Psychotropic drugs. Schaefer C, Peters P, Miller RK, eds. Drugs during pregnancy and lactation: Treatment options and risk assessment. San Francisco: Academic Press;2007.p.302-11. [CrossRef]15. Merks JH, van Karnebeek CD, Caron HN, Hennekam RC. Phenotypic abnormalities: terminology and classification. Am J Med Genet A 2003;123A(3):211-30. [CrossRef]16. Yaris F, Ulku C, Kesim M, Kadioglu M, Unsal M, Dikici MF, et al. Psychotropic drugs in pregnancy: a case-control study. Prog Neuropsychopharmacol Biol Psychiatry 2005;29(2): 333-8. [CrossRef]17. Einarson A, Choi J, Einarson TR, Koren G. Incidence ofmajor malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry 2009;54(4):242-6.18. Diav-Citrin O, Shechtman S, Ornoy S, Arnon J, Schaefer C, Garbis H, et al. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry 2005;66(3):317-22. [CrossRef]19. Reis M, Kaellen B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 2008;28(3):279-88. [CrossRef]20. Kornum JB, Nielsen RB, Pedersen L, Mortensen PB, Nørgaard M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2010;2:29-36. [CrossRef]21. Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011;118(1):111-20. [CrossRef]22. Hernandez-Diaz S. Prescription of medications during pregnancy: accidents, compromises, and uncertainties. Pharmacoepidemiol Drug Saf 2006;15(9):613-7. [CrossRef]23. Alwan S, Reefhuis J, Rasmussen SA, Friedman JM. Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol 2011;51(2):264-70. [CrossRef]24. Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 2007;29(5):918-26. [CrossRef]25. Tuccori M, Testi A, Antonioli L, Fornai M, Montagnani S, Ghisu N, et al. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. Clin Ther 2009;31(1):1426-53. [CrossRef]26. Andersohn F, Schade R, Willich SN, Garbe E. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology 2010;75(4):335-40. [CrossRef]27. Hill DS, Wlodarczyk BJ, Palacios AM, Finnell RH. Teratogenic effects of antiepileptic drugs. Expert Rev Neurother 2010;10(6):943-59. [CrossRef]28. Wichman CL. Atypical antipsychotic use in pregnancy: a retrospective review. Arch Womens Ment Health 2009;12(1):53-7. [CrossRef]29. Kieler H, Malm H, Artama M, Engeland A, Furu K, Gissler M, et al. Use of antidepressants and association with elective termination of pregnancy: population based case-control study. BJOG 2015;122(12):1618-24. [CrossRef]30. Coughlin CG, Blackwell KA, Bartley C, Hay M, Yonkers KA, Bloch MH. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet Gynecol 2015;125(5):1224-35. [CrossRef]31. Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di Gianantonio E, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008;66(5):695-705. [CrossRef]32. Walfisch A, Sermer C, Matok I, Einarson A, Koren G. Perception of teratogenic risk and the rated likelihood of pregnancy termination: association with maternal depression. Can J Psychiatry. 2011;56(12):761-7.33. Ozturk Z. Approaching pregnant women using medicine: risk of teratogenicity and counselling services. Surekli Tip Egitimi Dergisi 2014;23(5):201-5. (Turkish)34. Bhuvaneswar CG, Chang G, Epstein LA, Stern TA. Alcohol use during pregnancy: prevalence and impact. Prim Care Companion J Clin Psychiatry 2007;9(6):455-60. [CrossRef]35. Bakar C, Gundogar D, Karaman HI, Maral I. Prevalence and related risk factors of tobacco, alcohol and illicit substance use among university students. Eur J Psychiatry 2013;27(2):97-110.36. Ozyurt B, Dinc G. Alcohol drinking prevalance and related factors among school aged children in Manisa. Turk Silahli Kuvvetleri Koruyucu Hekim Bul 2006;5(2):61-71. (Turkish)37. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005;58(4):323-37. [CrossRef]38. Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 2011; 68(11):1104-12. [CrossRef]39. Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ 2013;346:f2059. [CrossRef]40. Downey G, Coyne JC. Children of depressed parents: an intergrative review. Psychol Bull 1990;108(1):50-76. [CrossRef]
APA öztürk z, Ölmez E, ÇAVUŞOĞLU T, GÖK Ş, VURAL K (2016). Safety of psychotropic medications in pregnancy: an observational cohort study. , 229 - 237.
Chicago öztürk zeynep,Ölmez Ercüment,ÇAVUŞOĞLU TUĞBA,GÖK ŞULE,VURAL Kamil Safety of psychotropic medications in pregnancy: an observational cohort study. (2016): 229 - 237.
MLA öztürk zeynep,Ölmez Ercüment,ÇAVUŞOĞLU TUĞBA,GÖK ŞULE,VURAL Kamil Safety of psychotropic medications in pregnancy: an observational cohort study. , 2016, ss.229 - 237.
AMA öztürk z,Ölmez E,ÇAVUŞOĞLU T,GÖK Ş,VURAL K Safety of psychotropic medications in pregnancy: an observational cohort study. . 2016; 229 - 237.
Vancouver öztürk z,Ölmez E,ÇAVUŞOĞLU T,GÖK Ş,VURAL K Safety of psychotropic medications in pregnancy: an observational cohort study. . 2016; 229 - 237.
IEEE öztürk z,Ölmez E,ÇAVUŞOĞLU T,GÖK Ş,VURAL K "Safety of psychotropic medications in pregnancy: an observational cohort study." , ss.229 - 237, 2016.
ISNAD öztürk, zeynep vd. "Safety of psychotropic medications in pregnancy: an observational cohort study". (2016), 229-237.
APA öztürk z, Ölmez E, ÇAVUŞOĞLU T, GÖK Ş, VURAL K (2016). Safety of psychotropic medications in pregnancy: an observational cohort study. Klinik Psikofarmakoloji Bülteni, 26(3), 229 - 237.
Chicago öztürk zeynep,Ölmez Ercüment,ÇAVUŞOĞLU TUĞBA,GÖK ŞULE,VURAL Kamil Safety of psychotropic medications in pregnancy: an observational cohort study. Klinik Psikofarmakoloji Bülteni 26, no.3 (2016): 229 - 237.
MLA öztürk zeynep,Ölmez Ercüment,ÇAVUŞOĞLU TUĞBA,GÖK ŞULE,VURAL Kamil Safety of psychotropic medications in pregnancy: an observational cohort study. Klinik Psikofarmakoloji Bülteni, vol.26, no.3, 2016, ss.229 - 237.
AMA öztürk z,Ölmez E,ÇAVUŞOĞLU T,GÖK Ş,VURAL K Safety of psychotropic medications in pregnancy: an observational cohort study. Klinik Psikofarmakoloji Bülteni. 2016; 26(3): 229 - 237.
Vancouver öztürk z,Ölmez E,ÇAVUŞOĞLU T,GÖK Ş,VURAL K Safety of psychotropic medications in pregnancy: an observational cohort study. Klinik Psikofarmakoloji Bülteni. 2016; 26(3): 229 - 237.
IEEE öztürk z,Ölmez E,ÇAVUŞOĞLU T,GÖK Ş,VURAL K "Safety of psychotropic medications in pregnancy: an observational cohort study." Klinik Psikofarmakoloji Bülteni, 26, ss.229 - 237, 2016.
ISNAD öztürk, zeynep vd. "Safety of psychotropic medications in pregnancy: an observational cohort study". Klinik Psikofarmakoloji Bülteni 26/3 (2016), 229-237.